VT
KRYS icon

Vise Technologies’s Krystal Biotech KRYS Stock Holding History

Vise Technologies’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$655K Buy
1,762
+338
+24% +$101K 0.01% 1008
2026
Q1 		$351K Hold
1,424
– – 0.01% 1065
2025
Q4 		$351K Buy
+1,424
New +$300K 0.01% 1071

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vise Technologies's KRYS Position: Q2 2026 in Review

Vise Technologies increased its Krystal Biotech (KRYS) stake by 24% in Q2 2026, buying an estimated $101K and bringing the position to 1,762 shares worth $655K. The position accounts for 0.01% of the portfolio, ranked #1008.

Vise Technologies first reported a position in KRYS in Q4 2025 and has held it in 3 quarters since. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Vise Technologies held 1,762 shares of Krystal Biotech worth $655K as of Q2 2026.
  • Vise Technologies bought 338 Krystal Biotech shares in Q2 2026, an estimated $101K.
  • Krystal Biotech made up 0.01% of Vise Technologies's portfolio in Q2 2026, its #1008 holding.
  • Vise Technologies first reported a position in Krystal Biotech in Q4 2025 and has held it in 3 quarters since.
  • 423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Vise Technologies's 13F filing for Q2 2026, filed 11 Aug 2026.